Neal JW - Search Results

1

SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.

Pennell NA, Neal JW, Chaft JE, Azzoli CG, Jänne PA, Govindan R, Evans TL, Costa DB, Wakelee HA, Heist RS, Shapiro MA, Muzikansky A, Murthy S, Lanuti M, Rusch VW, Kris MG, Sequist LV. Pennell NA, et al. Among authors: neal jw. J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16. J Clin Oncol. 2019. PMID: 30444685 Free PMC article. Clinical Trial.

2

Targeted therapies: optimal first-line therapy for NSCLC with EGFR mutations.

Neal JW, Sequist LV. Neal JW, et al. Nat Rev Clin Oncol. 2010 Feb;7(2):71-2. doi: 10.1038/nrclinonc.2009.191. Nat Rev Clin Oncol. 2010. PMID: 20118973 No abstract available.

3

First-line use of EGFR tyrosine kinase inhibitors in patients with NSCLC containing EGFR mutations.

Neal JW, Sequist LV. Neal JW, et al. Clin Adv Hematol Oncol. 2010 Feb;8(2):119-26. Clin Adv Hematol Oncol. 2010. PMID: 20386533 Review.

4

Exciting new targets in lung cancer therapy: ALK, IGF-1R, HDAC, and Hh.

Neal JW, Sequist LV. Neal JW, et al. Curr Treat Options Oncol. 2010 Jun;11(1-2):36-44. doi: 10.1007/s11864-010-0120-6. Curr Treat Options Oncol. 2010. PMID: 20676809 Review.

5

AMG-386, a selective angiopoietin-1/-2-neutralizing peptibody for the potential treatment of cancer.

Neal J, Wakelee H. Neal J, et al. Curr Opin Mol Ther. 2010 Aug;12(4):487-95. Curr Opin Mol Ther. 2010. PMID: 20677100

6

Cetuximab monotherapy in patients with advanced non-small cell lung cancer after prior epidermal growth factor receptor tyrosine kinase inhibitor therapy.

Neal JW, Heist RS, Fidias P, Temel JS, Huberman M, Marcoux JP, Muzikansky A, Lynch TJ, Sequist LV. Neal JW, et al. J Thorac Oncol. 2010 Nov;5(11):1855-8. doi: 10.1097/JTO.0b013e3181f0bee0. J Thorac Oncol. 2010. PMID: 20975380 Free article. Clinical Trial.

7

The SATURN trial: the value of maintenance erlotinib in patients with non-small-cell lung cancer.

Neal JW. Neal JW. Future Oncol. 2010 Dec;6(12):1827-32. doi: 10.2217/fon.10.156. Future Oncol. 2010. PMID: 21142856 Free PMC article. Clinical Trial.

8

One allele's loss is another's gain: alterations of NKX2-8 in non-small cell lung cancer.

Neal JW, Shaw AT. Neal JW, et al. Clin Cancer Res. 2011 Feb 15;17(4):638-9. doi: 10.1158/1078-0432.CCR-10-3081. Epub 2010 Dec 16. Clin Cancer Res. 2011. PMID: 21163872 Free PMC article.

9

Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.

Mak RH, Doran E, Muzikansky A, Kang J, Neal JW, Baldini EH, Choi NC, Willers H, Jackman DM, Sequist LV. Mak RH, et al. Among authors: neal jw. Oncologist. 2011;16(6):886-95. doi: 10.1634/theoncologist.2011-0040. Epub 2011 May 31. Oncologist. 2011. PMID: 21632451 Free PMC article.

10

Targeting FGFR, ephrins, Mer, MET, and PDGFR-α in non-small cell lung cancer.

Riess JW, Neal JW. Riess JW, et al. Among authors: neal jw. J Thorac Oncol. 2011 Nov;6(11 Suppl 4):S1797-8. doi: 10.1097/01.JTO.0000407562.07029.52. J Thorac Oncol. 2011. PMID: 22005534 Free article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

337 results

Search Page

Filters